^
    BIOMARKER:

    PIK3CA mutation + PTEN mutation

    i
    Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K, PTEN, Phosphatase and
    Entrez ID:
    5290; 5728
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas (NCT02523014)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    04/19/2022
    Initiation :
    08/01/2015
    Primary completion :
    10/01/2024
    Completion :
    10/01/2024
    PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • SMO • CDK6 • CCND3 • CCND2
    |
    PIK3CA mutation • PTEN mutation • CDKN2A mutation • PTCH1 mutation • NF2 mutation • AKT1 mutation • PIK3CA mutation + PTEN mutation • SMO mutation • CDK4 mutation
    |
    Verzenio (abemaciclib) • capivasertib (AZD5363) • Erivedge (vismodegib) • GSK2256098
    A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection (NCT03834740)
    Phase 1
    St. Joseph's Hospital and Medical Center, Phoenix
    Active, not recruiting
    Last update posted :
    03/14/2022
    Initiation :
    12/21/2018
    Primary completion :
    06/30/2022
    Completion :
    07/31/2022
    PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CDK4 • CDKN2B • PIK3R1 • PIK3C2B
    |
    PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation
    |
    everolimus • Kisqali (ribociclib)
    Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer (NCT03939897)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/25/2022
    Initiation :
    10/21/2019
    Primary completion :
    11/01/2022
    Completion :
    11/01/2022
    HER-2 • ER • PIK3CA • PGR • PTEN • CCND1
    |
    HER-2 amplification • PIK3CA mutation • HER-2 negative • PGR positive • PIK3CA mutation + PTEN mutation
    |
    Verzenio (abemaciclib) • fulvestrant • Aliqopa (copanlisib)
    Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery (NCT03317119)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/21/2022
    Initiation :
    04/11/2018
    Primary completion :
    09/23/2022
    Completion :
    09/23/2022
    BRAF • PIK3CA • PTEN
    |
    BRAF mutation • PIK3CA mutation • BRAF wild-type • RAS wild-type • PIK3CA mutation + PTEN mutation • RAS wild-type + BRAF wild-type
    |
    Mekinist (trametinib) • Lonsurf (trifluridine/tipiracil)
    A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors (NCT01195376)
    Phase 1
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    12/09/2020
    Initiation :
    10/01/2010
    Primary completion :
    07/01/2013
    Completion :
    07/01/2013
    PIK3CA • PTEN
    |
    PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA mutation + PTEN mutation
    |
    dactolisib (RTB101)
    Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer (NCT01277757)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    12/18/2018
    Initiation :
    03/01/2011
    Primary completion :
    08/01/2014
    Completion :
    08/01/2014
    ER • PIK3CA • PTEN
    |
    ER positive • PIK3CA mutation • PIK3CA mutation + PTEN mutation
    |
    MK-2206
    BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers (NCT01550380)
    Phase 2
    University of Utah
    Withdrawn
    Last update posted :
    07/30/2014
    Initiation :
    05/01/2014
    Primary completion :
    07/01/2014
    Completion :
    07/01/2014
    PIK3CA • PTEN
    |
    PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA mutation + PTEN mutation • PTEN-L
    |
    buparlisib (BKM120)